Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MikeStockon Mar 29, 2021 1:18pm
154 Views
Post# 32899076

what are we missing here?

what are we missing here?Something doesn't add up and I know I'm re-stating everything we've all said, but I feel like we're missing something. We can't fool ourselves and think we are smarter than that market and own this secret stock that is a millionaire maker in waiting. 
  • 75% of drugs don't make it to this stage. Historically a drug entering phase 3 has a $600M market cap
  • we have a China deal worth half our current market cap (yes, I know there are milestones)
  • $74M in cash 
  • recents execs who joined the team wouldn't have done it if they felt the risk was too high
  • we have several analysts putting a strong buy rating
  • Yes we aren't on NASDAQ, but is that the only thing holding back this stock?
  • We're up a penny on news that FDA has approved the start of phase 3 and no one is buying (88K shares traded so far today)
  • Was the wording of the release bad?  Was it missing key info?
I'm honestly so confused as to why.
<< Previous
Bullboard Posts
Next >>